



NDA 220320

**NDA APPROVAL**

MAP77 LLC  
Attention: Mansi A. Shah-Patel, PhD  
President  
2012 West Wellsgate Drive  
Oxford, MS 38655

Dear Dr. Shah-Patel:

Please refer to your new drug application (NDA) received May 22, 2025, and your amendments, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Atoncy (atomoxetine) oral solution.

This NDA provides for the use of Atoncy (atomoxetine) oral solution for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older.

### **APPROVAL & LABELING**

We have completed our review of this NDA. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [FDA.gov](http://www.fda.gov).<sup>1</sup> Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information, Instructions for Use, and Medication Guide) as well as annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry, *SPL Standard for Content of Labeling Technical Qs and As*.<sup>2</sup>

The SPL will be accessible via publicly available labeling repositories.

---

<sup>1</sup> <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

<sup>2</sup> We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

## **CARTON AND CONTAINER LABELING**

Submit final printed carton and container labeling that are identical to the enclosed carton and container labeling as soon as they are available, but no more than 30 days after they are printed. Please submit these labeling electronically according to the guidance for industry *SPL Standard for Content of Labeling Technical Qs & As*. For administrative purposes, designate this submission “**Final Printed Carton and Container Labeling for approved NDA 220320.**” Approval of this submission by FDA is not required before the labeling is used.

## **DATING PERIOD**

Based on the stability data submitted to date, the expiry dating period for Atocny (atomoxetine) oral solution shall be 24 months from the date of manufacture when stored at 20°C to 25°C.

The expiration date for the packaged product, Atocny (atomoxetine) oral solution plus oral dosing syringe and bottle adaptor, shall be dependent on the shortest expiration date of any component.

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA; 21 U.S.C. 355c), all applications for new active ingredients (which includes new salts and new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages younger than 4 years because necessary studies are impossible or highly impracticable. This is because of the low prevalence of ADHD in this age group.

We are deferring submission of your pediatric study for ages 4 years to 6 years for this application because this product is ready for approval for use in adults and pediatric patients ages 6 years to younger than 18 years and the pediatric study has not been completed.

Your deferred pediatric study required by section 505B(a) of the FDCA are required postmarketing study. The status of this postmarketing study must be reported annually according to 21 CFR 314.81 and section 505B(a)(4)(C) of the FDCA. This required study is listed below.

- 4973-1 Conduct a two-part study to 1) evaluate the pharmacokinetics (PK) of atomoxetine oral solution in pediatric patients ages 4 to <6 years old with attention deficit/hyperactivity disorder, and 2) conduct an adequately powered, double-blind, placebo-controlled, efficacy and safety study of atomoxetine oral solution in pediatric patients ages 4 to <6 years old with attention deficit/hyperactivity disorder with the proposed timeline:

Final Protocol Submission: 11/2026

Study Completion: 10/2028

Final Report Submission: 03/2029

FDA considers the term *final* to mean that the applicant has submitted a protocol, the FDA review team has sent comments to the applicant, and the protocol has been revised as needed to meet the goal of the study or clinical trial.<sup>3</sup>

Submit the protocol(s) to your PIND 175483 with a cross-reference letter to this NDA. Reports of this required pediatric postmarketing study must be submitted as an NDA or as a supplement to your approved NDA with the proposed labeling changes you believe are warranted based on the data derived from this study. When submitting the reports, please clearly mark your submission "**SUBMISSION OF REQUIRED PEDIATRIC ASSESSMENTS**" in large font, bolded type at the beginning of the cover letter of the submission.

We note that you have fulfilled the pediatric study requirement for ages 6 to younger than 18 years for this application.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. For information about submitting promotional materials, see the final guidance for industry, *Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs*.<sup>4</sup>

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the Prescribing Information, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at FDA.gov.<sup>5</sup> Information and Instructions for completing the form can be found at FDA.gov.<sup>6</sup>

---

<sup>3</sup> See the guidance for Industry *Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act (October 2019)*.

<https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

<sup>4</sup> For the most recent version of a guidance, check the FDA guidance web page at

<https://www.fda.gov/media/128163/download>.

<sup>5</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>

<sup>6</sup> <http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

Your product is a Part 3 combination product (21 CFR 3.2(e)); therefore, you must also comply with postmarketing safety reporting requirements for an approved combination product (21 CFR 4, Subpart B). Additional information on combination product postmarketing safety reporting is available at [FDA.gov](http://FDA.gov).<sup>7</sup>

## **COMPENDIAL STANDARDS**

A drug with a name recognized in the official United States Pharmacopeia or official National Formulary (USP-NF) generally must comply with the compendial standards for strength, quality, and purity, unless the difference in strength, quality, or purity is plainly stated on its label (see FD&C Act § 501(b), 21 USC 351(b)). FDA typically cannot share application-specific information contained in submitted regulatory filings with third parties, which includes USP-NF. To help ensure that a drug continues to comply with compendial standards, application holders may work directly with USP-NF to revise official USP monographs. More information on the USP-NF is available on USP's website.<sup>8</sup>

If you have any questions, contact Jenna Kim, Regulatory Project Manager, at [jiye.kim@fda.hhs.gov](mailto:jiye.kim@fda.hhs.gov).

Sincerely,

*{See appended electronic signature page}*

Bernard A. Fischer, MD  
Deputy Director  
Division of Psychiatry  
Office of Neuroscience  
Office of New Drugs  
Center for Drug Evaluation and Research

---

<sup>7</sup> <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>

<sup>8</sup> <https://www.uspnf.com/>

ENCLOSURES:

- Content of Labeling
  - Prescribing Information
  - Medication Guide
  - Instructions for Use
- Carton and Container Labeling

-----  
**This is a r r s a i f a A l c r i c r c r d ha was sig d  
l c r ically. F ll wi g his ar ma if s a i s f a y a d all  
l c r ic sig a ur s f r his l c r ic r c r d.**  
-----

/s/ A  
-----

BERN RD FISCHER  
03/20/2026 04:23:24 PMA